Study S001535

The Impact of Lixisenatide on Postprandial Glucose Tolerance in Pancreatectomised Subjects -a Delineation of Extrapancreatic Effects

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02640118
Acronym: Px-Lixi
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: DOUBLE
Status: COMPLETED
Enrollment: 24
Start: 2015-08
Primary completion: 2016-07
Lead sponsor: University Hospital, Gentofte, Copenhagen
Conditions: Diabetes After Total Pancreatectomy
Interventions: DRUG:Lixisenatide; DRUG:Lixisenatide-Placebo; OTHER:Standardized liquid meal
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

PPG excursions measured as incremental area under curve (iAUC) [-120,-45,-30,-15,0,5,10,15,20,25,30,40,50,60,70,80,90,105,120,135,150,180 minutes]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0017361	The GLP-1 receptor agonist lixisenatide reduces postprandial glucose in patients with diabetes secondary to total pancreatectomy: a randomised, placebo-controlled, double-blinded crossover trial. Juel CTB, Diabetologia	2020	Randomized trial	PMID 32394228 DOI	cites ClinicalTrials.gov:NCT02640118; registry reference DERIVED:32394228